%D8%A5%D9%86%D8%AA%D8%B1%D9%81%D9%8A%D8%B1%D9%88%D9%86%C4%B0nterferon%D0%86%D0%BD%D1%82%D1%8D%D1%80%D1%84%D0%B5%D1%80%D0%BE%D0%BD%E0%A6%87%E0%A6%A8%E0%A7%8D%E0%A6%9F%E0%A6%BE%E0%A6%B0%E0%A6%AB%E0%A7%87%E0%A6%B0%E0%A6%A8InterferonInterfer%C3%B3%D8%A6%DB%8C%D9%86%D8%AA%DB%95%D8%B1%D9%81%DB%8E%D8%B1%DB%86%D9%86InterferonInterferonInterferone%CE%99%CE%BD%CF%84%CE%B5%CF%81%CF%86%CE%B5%CF%81%CF%8C%CE%BD%CE%B7InterferonKategorio:InterferonoInterfer%C3%B3nInterferoonidInterferoi%D8%A7%DB%8C%D9%86%D8%AA%D8%B1%D9%81%D8%B1%D9%88%D9%86InterferoniInterf%C3%A9ronInteirf%C3%A9ar%C3%B3nInterfer%C3%B3n%D7%90%D7%99%D7%A0%D7%98%D7%A8%D7%A4%D7%A8%D7%95%D7%9F%E0%A4%87%E0%A4%82%E0%A4%9F%E0%A4%B0%E0%A4%AB%E0%A5%87%E0%A4%B0%E0%A5%89%E0%A4%A8InterferonEnt%C3%A8fewonInterferon%D4%BB%D5%B6%D5%BF%D5%A5%D6%80%D6%86%D5%A5%D6%80%D5%B8%D5%B6InterferonInterferoni%E3%82%A4%E3%83%B3%E3%82%BF%E3%83%BC%E3%83%95%E3%82%A7%E3%83%AD%E3%83%B3Interferon%E1%83%98%E1%83%9C%E1%83%A2%E1%83%94%E1%83%A0%E1%83%A4%E1%83%94%E1%83%A0%E1%83%9D%E1%83%9C%E1%83%98%D0%98%D0%BD%D1%82%D0%B5%D1%80%D1%84%D0%B5%D1%80%D0%BE%D0%BD%E0%B2%87%E0%B2%82%E0%B2%9F%E0%B2%B0%E0%B3%8D%E0%B2%AB%E0%B3%86%E0%B2%B0%E0%B2%BE%E0%B2%A8%E0%B3%8D%EC%9D%B8%ED%84%B0%ED%8E%98%EB%A1%A0%C3%8Enterferon%D0%98%D0%BD%D1%82%D0%B5%D1%80%D1%84%D0%B5%D1%80%D0%BE%D0%BD%D0%98%D0%BD%D1%82%D0%B5%D1%80%D1%84%D0%B5%D1%80%D0%BE%D0%BDInterferonInterferony
about
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin (2013-03-31)A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (2011-09-20)Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (2005-02-28)Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia (1996-02-29)A Prospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV PneumoniaDiscontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV InfectionRituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell LymphomaEvaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)Xiyanping Injection for the Treatment of New Coronavirus Infected PneumoniaThe Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by SurgeryLopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV TreatmentEfficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus PatientsEvaluation of Ganovo Combined With Ritonavir in the Treatment of Novel Coronavirus InfectionMultiple Sclerosis: Chi3L1 and Treatment EfficacyA Cohort Study on Long-term Clinical Outcomes of Antiviral Therapy in Patients With Chronic Hepatitis B and CirrhosisAn Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis CInterferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host DiseaseExperimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical StaffTrial of Treatments for COVID-19 in Hospitalized AdultsAn Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical TrialClinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 InfectionA Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With EntecavirUS PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT AutoinjectorUmifenovir in Hospitalized COVID-19 PatientsInterferon Beta 1a in Hospitalized COVID-19 PatientsPegylated Interferon Lambda Treatment for COVID-19Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast CancerRintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer PatientsNivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar CancerDouble Therapy With IFN-beta 1b and HydroxychloroquineThe Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTrial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) InfectionInterferon Lambda Therapy for SARS-CoV-2 InfectionStudy of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus InfectionA Breast Cancer Vaccine (SV-BR-1-GM) in Combination With Pembrolizumab for the Treatment of Persistent, Recurrent, or Metastatic Breast Cancer
P4844
Hemadsorption cell-counting asay of interferonAntagonistic activity of poly (4-Vinylpyridine-N-oxide) to the inhibition of viral interferon induction by asbestos fibresNew antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1Interferon signaling and treatment outcome in chronic hepatitis CPeginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialMechanism of action of interferon and ribavirin in treatment of hepatitis CInterferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical
P921
Q86167643-3736ECD6-0177-403E-9706-DEB09B24E306Q86170326-9D902217-C3D6-4E36-96B3-7939F7A85603Q86248837-63064134-74EF-44BE-94A8-ACC811B5FD43Q86252044-4D0D1EF8-DA04-4A91-B4BC-B95E3CB6C7AAQ86260832-167CE4D6-3C69-43B8-A7A2-57C100AB40EBQ86263927-9D5B3C87-A405-40D2-9E1D-2D252EF020F4Q86268957-E3B74DA6-F156-4344-935A-F45B685BCCBEQ86271504-16B5C4E0-6149-4F42-983C-238D6836F162Q86273686-C29B2578-3F73-46DD-B32B-1C7B636E7381Q86281789-B8F7ABCB-D166-4FA3-97F2-A813DD1C4B78Q86292325-8C2F2968-69D4-4AE7-B595-9AC1753DF49DQ86294181-37634E56-BD97-4186-9A74-DDFFAF9C6D2CQ87078255-F6E11CD6-6DE8-4411-845A-345AFE2F2EC0Q87078585-D4880BE2-5D00-4D3A-8C9A-0470F33B0994Q87078911-2E1AC9EA-4E9A-49E5-8F2F-27B9FF38B079Q87931783-01AC7B6F-0B94-40F7-803D-49FE378F1DD3Q87931817-AF87D16D-95ED-4512-B3DA-A9AAE60C91E9Q89153153-09C0C4A0-04A1-4BCF-B53F-B77E892A0C3CQ89154960-A2BD8BFE-E3C2-4E1F-9989-C50A9EFDECA9Q89155499-7E893A90-5007-41C5-83DC-ED96B5B9D6B6Q90692483-377F2324-5940-410B-A9A6-A159DDC548FFQ92391952-FF085B81-F665-412E-8B3D-3E2D213F5AE8Q92391977-95D2043C-4DE4-4E5A-B8A1-EA9DAEC97FD8Q92392155-739D229A-1A37-4988-98B2-D8FAE320B7DEQ92392199-4CF94663-5CDC-43BE-8FED-F7C19A46E181Q92392200-541EC604-372A-44FC-B6AC-EC3DB0158F52Q92392273-56973439-5766-4719-A428-88324038652BQ93422634-95B9BE8A-1229-4A40-B49D-ACA5DB36370DQ93581123-A5ED2991-B9D6-4F63-8D0C-0A04EF3D5E69Q93704419-36722F8D-E299-4BC4-B0BA-EEDC5A3A2EB4Q93704592-E47A5D60-5343-45F4-865F-BBAE3664934EQ93704596-87B4B0BC-1F9C-443E-95CD-2E4284CCC709Q94234614-7704A441-4A15-4EA7-883D-B709C78B90ECQ94486177-2B891F33-5E78-4F5E-9B7E-74D157B17F8CQ96055726-7AEA74D4-7AFB-4980-8900-9579EB161DF1Q96143398-2C6AAF41-C497-4EB5-8574-2545A214C539
P4844
Q23918656-2C927302-F577-46FE-AD21-11E44AC96A94Q23922472-4B79D73B-0C57-4964-A3AF-063117B2F595Q24300907-51bcbdb0-4b14-3648-11e7-73e0eebabc72Q27486083-3adee872-4c4a-0b48-dc7b-d273ae5d8ab0Q27860949-8df57b62-4a55-3e71-415b-25485a02ba64Q29619805-be0ee652-4aa4-50ea-1a51-aa5e75a554fdQ36510607-fb72b1e7-4b03-c4dd-e3d9-80932331f42f
P921
description
Protéine produite par les cellules du système immunitaire inné
@fr
eiwitten, aangemaakt en uitges ...... ezigheid van ziektenverwekkers
@nl
famiglia di proteine prodotte ...... i ma anche di cellule tumorali
@it
grupa białek działających przeciwzakaźnie i przeciwnowotworowo
@pl
interferon
@hy
protein producerat av kroppens celler som svar på attacker
@sv
proteinoj de imuna sistemo
@eo
proteins made and released by host cells in response to the presence of pathogens
@en
tipo de proteínas
@es
vücut hücreleri tarafından bazı zararlılara karşı üretilen protein
@tr
name
Entèfewon
@ht
Inteirféarón
@ga
Interferoi
@eu
Interferon & asid trichloracetic
@ms
Interferon
@bs
Interferon
@da
Interferon
@hr
Interferon
@hu
Interferon
@id
Interferon
@jv
type
label
Entèfewon
@ht
Inteirféarón
@ga
Interferoi
@eu
Interferon & asid trichloracetic
@ms
Interferon
@bs
Interferon
@da
Interferon
@hr
Interferon
@hu
Interferon
@id
Interferon
@jv
altLabel
Avonex
@de
Beta interferone
@it
IFN
@cs
IFN
@en
IFN
@es
IFN
@ja
IFN
@nl
IFN
@nn
IFN
@pl
IFN
@ru
prefLabel
Entèfewon
@ht
Inteirféarón
@ga
Interferoi
@eu
Interferon & asid trichloracetic
@ms
Interferon
@bs
Interferon
@da
Interferon
@hr
Interferon
@hu
Interferon
@id
Interferon
@jv
P672
P2581
P349
P486
P508
P6366
P646
P1296
P1417
science/interferon
P2167
P231
P232
P2566
100.029.724